Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction

Phytotherapy Research

Volumn 20, Issue 2, 2006, Pages 140-146

  Naidu, Pattipati S ^a   Singh, Amanpreet ^a   Kulkarni, Shrinivas K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Oxidative stress; Reserpine; Tardive dyskinesia; VCMs; Withania somnifera

Indexed keywords

CATALASE; GLUTATHIONE; NEUROLEPTIC AGENT; RESERPINE; SUPEROXIDE DISMUTASE; WITHANIA SOMNIFERA EXTRACT;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG ISOLATION; HUMAN; LIPID PEROXIDATION; MALE; MASTICATION; MAZE TEST; MEMORY CONSOLIDATION; NONHUMAN; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLANT ROOT; RAT; TARDIVE DYSKINESIA; TONGUE; WITHANIA SOMNIFERA;

ANIMALS; ANTIOXIDANTS; BRAIN; COGNITION DISORDERS; DYSKINESIA, DRUG-INDUCED; GLUTATHIONE; MALE; MALONDIALDEHYDE; PHYTOTHERAPY; PLANT EXTRACTS; PLANT ROOTS; RATS; RATS, WISTAR; RESERPINE; WITHANIA;

ANIMALIA; WITHANIA SOMNIFERA;

EID: 33144467788     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1823     Document Type: Article

References (54)

1. Abilio VC, Araujo CCS, Bergamo M et al. 2003. Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats. Prog Neuropschopharmacol Biol Psychiatry 27: 109-114.
2. Andreassen OE, Jorgensen HA. 2000. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Prog Neurobiol 61: 525-541.
3. Behl C, Lezoulach F, Widmann M, Rupprecht R, Holsboer F. 1996. Oxidative stress-resistant cells are protective against haloperidol toxicity. Brain Res 717: 193-195.
4. Benzi G, Moretti A. 1995. Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and glutathione system. Free Radic Biol Chem 19: 77-101.
5. Bergamo M, Abilio VC, Queiroz CMT, Barbosa Jr HM, Abdanur LRA, Frussa-Filho R. 1997. Effects of age on a new animal model of tardive dyskinesia. Neurobiol Aging 18: 623-629.
6. Bhattacharya A, Ghosal S, Bhattacharya SK. 2001. Antioxidant effect of Withania somnifera glycowithanolides in chronic foot shock induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and Striatum. J Ethnopharmacol 74: 1-6.
7. Bhattacharya SK, Goel RK, Kaur R, Ghosal S. 1987. Antistress activity of sinoidosides VII and VIII. New acylsterylglycosides from W. somnifera. Phytother Res 1: 32-37.
8. Bhattacharya SK, Kumar A, Ghosal A. 1995. Effects of glycowithanolids from Withania somnifera in an animal model of Alzheimer's disease and perturbed central cholinergic markers of cognition in rats. Phytother Res 9: 110-113.
9. Bhattacharya SK, Satyan KS, Ghosal A. 1997. Antioxidant activity of glycowithanolids from Withania somnifera. Indian J Exp Biol 35: 236-239.
10. Burger ME, Alves A, Callegari L et al. 2003. Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. Prog Neuropschopharmacol Biol Psychiatry 27: 135-140.
11. Calvente PRV, Araujo CCS, Bergamo M et al. 2002. The mitochondrial toxin 3-nitropropionic acid aggravates reserpine-induced oral dyskinesia in rats. Prog Neuropschopharmacol Biol Psychiatry 26: 401-405.
12. Casey DE. 2000 Tardive dyskinesia: Pathophysiology and animal models. J Clin Psychiat 61: 5-9.
13. Dhuley JN. 1998. Effect of Ashwagandha on lipid peroxidation in stress-induced animals. J Ethnopharmacol 60: 173-178.
14. Ellman GL. 1959. Tissue sulfhydryl groups. Arch Biochem Biophys 82: 70-77.
15. Gallhofer B, Bauer U, Kriger S, Gruppe H. 1996. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropscyhopharmacol 6 (Suppl. 2): S13-S20.
16. Ghosal S, Lal J, Srivastava RS et al. 1989. Immunostimulatory and CNS effects of sitoindosides IX and X. two new glycowithanoloids from Withania somnifera. Phytother Res 3: 201-206.
17. Gunne LM, Andren PE. 1993. An animal model for co existing tardive dyskinesia and tardive parkinsonism: A glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol 16: 90-95.
18. Ioth J, Nabeshima T, Kameyama T. 1991. Utility of an elevated plus-maze for dissociation of amnesic and behavioural effects of drugs in mice. Eur J Pharmacol 194: 71-74.
19. Kleeb SR, Rizzo MS, Dagli MLZ, Frussa-Filno R. 1999. Haloperidol increases spreading and nitric oxide production in macrophages from tumor-bearing mice: a possible mechanism for its antitumoral effect. Int J Immunopharmacol 21: 575-580.
20. Kono Y. 1978. Generation of superoxide radical during autooxidation of hydroxylamine and an assay for superoxide dismutase. Arch Biochem Biophys 186: 189-195.
21. Krabbendam L, van Harten PN, Picus I, Jolies J. 2000. Tardive dyskinesia is associated with impaired retrieval from long-term memory: the Curacao experimental syndromes study: IV. Schizophr Res 42: 41-46.
22. Kulkarni SK, Naidu PS. 2001. Tardive dyskinesia: An update. Drugs of Today 37: 97-119.
23. Kulkarni SK, Sharma A, Verma A, Ticku MK. 1993. GABA receptor mediated anticonvulsant action of Withania somnifera root extract. Indian Drugs 30: 305-312.
24. Kulkarni SK, Verma A. 1993. Aswagandha and Bramhi: Nootropic and de-addiction profile of psychotropic indigenous plants. Drugs Today 29: 257-263.
25. Lohr JB. 1991. Oxygen free radicals and neuropsychiatric illness. Arch Gen Psychiatry 48: 1097-1106.
26. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. 1990. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 28: 535-539.
27. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin-Phenol reagent. J Biol Chem 193: 265-275
28. Luck H. 1971. Catalase. In Methods of Enzymatic Analysis, Bergmeyer HU (ed.). Academic Press: New York; 885-893.
29. Nagashyana N, Sankarankutty P, Nampoothiri MRV, Moahan P, Mohan Kumar P. 2000. Association of L-dopa with recovery following Ayuervedic medication in Parkinson's disease. J Neurol Sci 176: 1121-1127.
30. Naidu PS, Kulkarni SK. 2001a Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements. Eur J Pharmacol 428: 81-86.
31. Naidu PS, Kulkarni SK. 2001b. Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats. Eur J Pharmacol 430: 295-298.
32. Naidu PS, Kulkarni SK. 2001c. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): Possible involvement of calcium and nitric oxide. Behav Pharmacol 12: 209-216.
33. Naidu PS, Kulkarni SK. 2002. Reversal of reserpine-induced vacuous chewing movements by ethanol: Possible GABA-A receptor modulation. Brain Pharmacol: 189-195.
34. Naidu PS, Singh A, Kulkarni SK. 2002. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms. Br J Pharmacol 136: 193-200.
35. Neisewander JL, Castaneda E, Davis DA. 1994. Dose dependant differences in the development of reserpine-induced oral dyskinesia in rats: support for a rat model of tardive dyskinesia. Psychopharmacology 116: 79-84.
36. Neisewander JL, Castaneda E, Davis DA, Elson HJ, Sussman AN. 1996. Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia. Eur J Pharmacol 305: 13-21.
37. Neisewander JL, Lucki I, McGonigle P. 1991a. Behavioural and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats. J Pharmacol Exp Ther 257: 850-860.
38. Neisewander JL, Lucki I, McGonigle P. 1991b. Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. Brain Res 558: 27-35.
39. Pandey VN. 1985. In Phytochemical Investigation of Certain Medicinal Plants Used in Ayurveda Central Council for Research in Ayurveda and Sidda. Government of India: New Delhi; 31-33.
40. Pourcher E, Cohen H, Cohen D, Baruch P, Bouchard RH. 1993. Organic brain dysfunction and cognitive deficits in young schizophrenic patients with tardive dyskinesia. Brain Cogn 23: 81-87.
41. Queiroz CMT, Frussa-Filho R. 1999. Effects of buspirone on an animal models of tardive dyskinesia. Prog Neuropscychopharmacol Biol Psychiatry 23: 1405-1418.
42. Queiroz CMT, Piovezan RD, Frussa-Filho R. 1998. Reserpine does not induce orofacial dyskinesia in spontaneously hypertensive rats. Eur J Pharmcol 356: 105-108.
43. Raghavendra V, Kulkarni SK. 2001. Possible antioxidant mechanism in melatonin reversal of aging and chronic ethanol-induced amnesia in plus-maze and passive avoidance memory tasks. Free Radic Biol Med 30: 595-602.
44. Raghavendra V, Naidu PS, Kulkarni SK. 2001. Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors. Brain Res 904: 149-152.
45. Reddy DS, Kulkarni SK. 1998. Possible role of nitric oxide in the nootropic and antiamnesic effects of neurosteroids on aging- and dizocilpine-induced learning impairment. Brain Res 799: 215-229.
46. Silva RH, Abilio VC, Torres-Leite D et al. 2002. Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice. Behav Brain Res 132: 172-177.
47. Sorokin JE, Giordani B, Mohs RC et al. 1988 Memory impairment in schizophrenic patients with tardive dyskinesia. Biol Psychiatry 23: 129-135.
48. Stip E, Lussier I. 1996. The heterogeneity of memory dysfunction in schizophrenia. Can J Psychiatry 41 (7 Suppl. 1): S14-S20.
49. Struve FA, Willner AE. 1983. Cognitive dysfunction and tardive dyskinesia. Br J Psychiatry 143: 597-600.
50. Sussman AN, Tran-Nguyen LTL, Neisewander JL. 1997. Acute reserpine administration elicits long-term spontaneous oral dyskinesia. Eur J Pharmacol 337: 157-160.
51. Uhrbrand L, Faurbye A. 1960. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacology 1: 108-418.
52. Vital MABF, Frussa-Filho R, Palerrno-Neto J. 1997. Effects of monosialoganglioside on a new model of tardive dyskinesia. Prog Neuropscychopharmacol Biol Psychiatry 21: 116-1179.
53. Waddington JL, Youssef HA. 1996. An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms. Am J Psychiatry 143: 1162-1165.
54. Wills ED. 1966. Mechanism of lipid peroxide formation in animal tissues. Biochem J 99: 667-676.